DSRIP Chapter Updates

2023-10-09

# TO DO

* ☐ Color pallete
* ☐ Verify dates and years are correct
* ☐ check table rounding
* ☐ check table when missing
* ☐ Need to add oeq.R from APM to emilys path

# Questions




* Should I change axis on 1.4 from 17, 18, etc to the same DYY (YYYY)

###### Table II.7 RHP participation rates by year

| RHP | DY9 (2020) | DY10 (2021) | DY11 (2022) | Total |
| --- | --- | --- | --- | --- |
| 1 | 85.0%(17) | 50.0%(10) | 95.0%(19) | 20 |
| 2 | 80.0%(12) | 66.7%(10) | 86.7%(13) | 15 |
| 3 | 76.0%(19) | 72.0%(18) | 72.0%(18) | 25 |
| 4 | 81.2%(13) | 37.5%(6) | 100.0%(16) | 16 |
| 5 | 90.0%(9) | 50.0%(5) | 70.0%(7) | 10 |
| 6 | 77.3%(17) | 72.7%(16) | 90.9%(20) | 22 |
| 7 | 100.0%(7) | 71.4%(5) | 85.7%(6) | 7 |
| 8 | 58.3%(7) | 83.3%(10) | 83.3%(10) | 12 |
| 9 | 59.1%(13) | 86.4%(19) | 95.5%(21) | 22 |
| 10 | 62.5%(15) | 91.7%(22) | 95.8%(23) | 24 |
| 11 | 78.6%(11) | 71.4%(10) | 92.9%(13) | 14 |
| 12 | 73.5%(25) | 64.7%(22) | 88.2%(30) | 34 |
| 13 | 76.9%(10) | 84.6%(11) | 84.6%(11) | 13 |
| 14 | 100.0%(8) | 75.0%(6) | 87.5%(7) | 8 |
| 15 | 100.0%(8) | 62.5%(5) | 100.0%(8) | 8 |
| 16 | 100.0%(7) | 71.4%(5) | 85.7%(6) | 7 |
| 17 | 83.3%(10) | 91.7%(11) | 91.7%(11) | 12 |
| 18 | 100.0%(6) | 100.0%(6) | 100.0%(6) | 6 |
| 19 | 81.8%(9) | 90.9%(10) | 90.9%(10) | 11 |
| 20 | 75.0%(3) | 25.0%(1) | 100.0%(4) | 4 |
| Texas | 77.9%(226) | 71.7%(208) | 89.3%(259) | 290 |


###### Measure 1.1.2

(JSD, RS, DSA)






###### Figure II.3. Strength of network ties

(Measure 1.1.3 - Density)






###### Figure II.4. Average density of network ties

(JSD, RS, DSA)



###### Figure II.5. Average centralization of network ties



## Measure 1.1.6


Attitude toward Collaboration

To understand the attitudes of DSRIP-participating providers toward DSRIP’s impact on collaborative relationships, specifically care coordination, providers were asked about the extent to which they agreed or disagreed with the following statements:

• DSRIP has increased the level of care coordination between different DSRIP providers.


• DSRIP has increased the level of care coordination between DSRIP and non-DSRIP providers.

###### DSRIP has increased the level of care coordination between different DSRIP providers.



Difference between 2020 responses and 2022 responses is not statistically significant after conducting Wilcoxon Rank Sum Test (p = 0.952 V = 30795.)

###### DSRIP has increased the level of care coordination between DSRIP and non-DSRIP providers.



Difference between 2020 responses and 2022 responses is not statistically significant after conducting Wilcoxon Rank Sum Test (p = 0.213 V = 32421.)

###### Table II.11 Health Information Exchanges used by Participating Providers

| Organization | DY9 (2020) | DY10 (2021) | DY11 (2022) |
| --- | --- | --- | --- |
| Care- Quality | 0% (0) | 4% (3) | 6% (5) |
| Cerner Direct | 0% (0) | 6% (4) | 0% (0) |
| Commonwell Health Alliance | 6% (3) | 8% (5) | 6% (5) |
| Epic/ Care Everywhere | 8% (4) | 4% (3) | 2% (1) |
| Greater Houston Healthconnect | 26% (14) | 28% (17) | 20% (17) |
| HIE Texas | 2% (1) | 2% (1) | 26% (21) |
| Healthcare Access San Antonio (HASA) | 20% (10) | 28% (17) | 22% (18) |
| Integrated Care Collaboration (ICC) | 2% (1) | 4% (3) | 4% (3) |
| OTHER | 18% (9) | 2% (1) | 2% (2) |
| Pasa Del Norte Health Information Exchange (PHIX) | 12% (6) | 8% (5) | 8% (7) |
| Rio Grand HIE | 8% (4) | 4% (3) | 4% (3) |


Total number of organization counts for 2020 = 52, 2021 = 62, 2022 = 82.

###### Table II.12 Number and percentage of external organizations that provided DSRIP data


| Organization | DY9 (2020) | DY10 (2021) | DY11 (2022) |
| --- | --- | --- | --- |
| Community Clinic | 16% (11) | 10% (8) | 12% (8) |
| Contracted Providers | 18% (12) | 16% (12) | 16% (11) |
| Epic | 2% (1) | 6% (4) | 2% (2) |
| Federal Agency | 8% (6) | 10% (8) | 12% (8) |
| Inpatient Data | 4% (3) | 0% (0) | 2% (2) |
| MedicalSchool or University | 6% (4) | 4% (3) | 2% (1) |
| Other | 10% (7) | 8% (6) | 10% (7) |
| Other HIE Network | 4% (3) | 8% (6) | 6% (4) |
| Outpatient Data | 6% (4) | 6% (5) | 8% (5) |
| Regional HIE | 14% (9) | 6% (5) | 12% (8) |
| State Agency | 12% (8) | 22% (16) | 16% (11) |

Total number of organization counts for 2020 = 68, 2021 = 73, 2022 = 67.

###### Figure II.4 Overall Provider Achievement for A1-508 Rate of ED Visits for Diabetes




###### Figure II.5 Population Impact: Change in Weighted Mean Rate: A1-508 Rate of ED Visits for Diabetes




Difference between weighted baseline rate and 2021 weighted rate is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 192, p = 0.033).

###### Figure II.6 Overall Provider Achievement for A2-509 Rate of ED Visits for CHF, Angina, and Hypertension




###### Figure II.7 Population Impact: Change in Weighted Mean Rate: A2-509 Rate of ED Visits for CHF, Angina, and Hypertension




Difference between weighted baseline rate and 2021 weighted rate is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 64, p = 0.052).

###### Figure II.8 Overall Provider Achievement for H2-510 Rate for Behavioral Health and Substance Abuse




###### Figure II.9 Population Impact: Change in Weighted Mean Rate: H2-510 Rate for Behavioral Health and Substance Abuse

(Comparison of Real and Target Weighted Mean Rates)




Difference between weighted baseline rate and 2021 weighted rate is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 15, p = 0.062).

###### Figure II.10 Overall Provider Achievement for C1-502 Rate for the Adult Acute Composite Indicator




###### Figure II.11 Population Impact: Change in Weighted Mean Rate: C1-502 Rate for the Adult Acute Composite Indicator

(Comparison of Real and Target Weighted Mean Rates)




Difference between weighted baseline rate and 2021 weighted rate is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 136, p = 0.003).

###### Figure II.12 Overall Provider Achievement for D1-503 Rate for the Child Acute Composite Indicator



###### Figure II.13 Population Impact: Change in Weighted Mean Rate: D1-503 Rate for the Child Acute Composite Indicator


(Comparison of Real and Target Weighted Mean Rates)



Difference between weighted baseline rate and 2021 weighted rate is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 41, p = 0.193).

###### Figure II.14 Potentially Preventable Admissions


(PPA) **Change y axis**



Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 207, p < .05).

###### Figure II.15 Potentially Preventable Readmissions


(PPR)



Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 206, p < .05).

###### Figure II.16 Potentially Preventable Complications


(PPC)



Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 207, p < .05).

###### Figure II.17 Potentially Preventable ED Visits Actual-to-Expected Ratios

(PPV)



Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 210, p < .05).

# Appendix

###### Table B.20 Provider Measure Achievement: A1-508 Rate of ED Visits for Diabetes


###### Rate of Emergency Department Visits for Diabetes (A1-508: DSRIP Category C Measure 1.3.1)

###### Summary Statistics by Year and Measure Achievement: Rate of Emergency Department Visits for Diabetes

| Measure Achievement | DY7 % (#) (n = 22) | DY8 % (#) (n = 22) | DY9 % (#) (n = 22) | DY10 % (#) (n = 22) |
| --- | --- | --- | --- | --- |
| Not Met | 22.7 (5) | 4.5 (1) |  |  |
| Partially Met | 4.5 (1) | 31.8 (7) | 22.7 (5) | 36.4 (8) |
| Met | 72.7 (16) | 63.6 (14) | 77.3 (17) | 63.6 (14) |

###### Figure B.6 Change in Unweighted Mean Rate: A1-508 Rate of ED Visits for Diabetes

(Comparison of Real and Target Mean Rates)



Difference between baseline rate and 2021 rate is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 186, p = 0.054).


###### Table B.21 Provider Measure Achievement: A2-509 Rate of ED Visits for CHF, Angina, and Hypertension

###### Summary Statistics by Year and Measure Achievement: Rate of Emergency Department Visits for CHF, Angina, and Hypertension

| Measure Achievement | DY7 % (#) (n = 12) | DY8 % (#) (n = 12) | DY9 % (#) (n = 12) | DY10 % (#) (n = 12) |
| --- | --- | --- | --- | --- |
| Not Met | 8.3 (1) |  |  |  |
| Met | 91.7 (11) | 83.3 (10) | 83.3 (10) | 83.3 (10) |
| Partially Met |  | 16.7 (2) | 16.7 (2) | 16.7 (2) |

###### Figure B.3 Change in Unweighted Mean Rate: A2-509 Rate of ED Visits for CHF, Angina, and Hypertension

(Comparison of Real and Target Mean Rates)



Difference between baseline rate and 2021 rate is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 62, p = 0.077).


###### Table B.22 Provider Measure Achievement: H2-510 Rate of Emergency Department Visits for Behavioral Health and Substance Abuse

###### Summary Statistics by Year and Measure Achievement: Rate of Emergency Department Visits for Behavioral Health and Substance Abuse

| Measure Achievement | DY7 % (#) (n = 5) | DY8 % (#) (n = 5) | DY9 % (#) (n = 5) | DY10 % (#) (n = 5) |
| --- | --- | --- | --- | --- |
| Not Met | 60 (3) |  |  |  |
| Met | 40 (2) | 40 (2) | 40 (2) | 40 (2) |
| Partially Met |  | 60 (3) | 60 (3) | 60 (3) |

###### Figure B.4 Change in Unweighted Mean Rate: H2-510 Rate of Emergency Department Visits for Behavioral Health and Substance Abuse

(Comparison of Real and Target Mean Rates)



Difference between baseline rate and 2021 rate is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 10, p = 0.625).


###### Table B.23 Provider Measure Achievement: C1-502 PQI 91 Adult Acute Composite Indicator

###### Summary Statistics by Year and Measure Achievement: Prevention Quality Indicator 91: Adult Acute Composite Indicator

| Measure Achievement | DY7 % (#) (n = 17) | DY8 % (#) (n = 17) | DY9 % (#) (n = 17) | DY10 % (#) (n = 17) |
| --- | --- | --- | --- | --- |
| Met | 100 (17) | 100 (17) | 100 (17) | 100 (17) |

###### Figure B.5 Change in Unweighted Mean Rate: C1-502 PQI 91 Adult Acute Composite Indicator

(Comparison of Real and Target Mean Rates)



Difference between baseline rate and 2021 rate is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 144, p = 0.001).


###### Table B.24 Provider Measure Achievement: D1-503 PDI 91 Child Acute Composite Indicator

###### Summary Statistics by Year and Measure Achievement: Pediatric Quality Indicator 91: Child Acute Composite Indicator

| Measure Achievement | DY7 % (#) (n = 10) | DY8 % (#) (n = 10) | DY9 % (#) (n = 10) | DY10 % (#) (n = 10) |
| --- | --- | --- | --- | --- |
| Not Met | 20 (2) |  |  |  |
| Met | 80 (8) | 80 (8) | 80 (8) | 60 (6) |
| Partially Met |  | 20 (2) | 20 (2) | 40 (4) |

###### Figure B.6 Change in Unweighted Mean Rate: D1-503 PDI 91 Child Acute Composite Indicator

(Comparison of Real and Target Mean Rates)



Difference between baseline rate and 2021 rate is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 26, p = 0.922).

###### Table B.25 Summary Statistics by Year: Potentially Preventable Admissions (PPA)

###### Summary Statistics by Year: 1.4.1 Potentially Preventable Admissions (PPA)

| Year | Sample Size | Unweighted Mean (SD) | Unweighted Median (IQR) | Weighted Mean (SD) | Weighted Median (IQR) |
| --- | --- | --- | --- | --- | --- |
| 17 | 20 | 0.813 (0.2234) | 0.7793 (0.3257) | 0.1251 (0.0391) | 0.1337 (0.0606) |
| 18 | 20 | 0.7826 (0.2271) | 0.7588 (0.2225) | 0.1134 (0.0401) | 0.1196 (0.0383) |
| 19 | 20 | 0.8021 (0.2104) | 0.8002 (0.2085) | 0.121 (0.0436) | 0.108 (0.0408) |
| 20 | 20 | 0.6058 (0.2106) | 0.5536 (0.1899) | 0.0823 (0.0373) | 0.0778 (0.0283) |

Difference between 2017 and 2020 unweighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 207, p < .05). Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 207, p < .05).

###### Table B.26 Summary Statistics by Year: Potentially Preventable Readmissions (PPR)

###### Summary Statistics by Year: 1.4.2 Potentially Preventable Readmissions (PPR)

| Year | Sample Size | Unweighted Mean (SD) | Unweighted Median (IQR) | Weighted Mean (SD) | Weighted Median (IQR) |
| --- | --- | --- | --- | --- | --- |
| 17 | 20 | 33.8849 (10.9253) | 32.8495 (11.4559) | 55.3844 (15.7856) | 52.639 (21.5503) |
| 18 | 20 | 35.6727 (10.5787) | 33.978 (12.4672) | 61.3725 (16.5233) | 61.4947 (19.1256) |
| 19 | 20 | 38.7964 (11.7138) | 37.3788 (12.1545) | 62.4717 (16.9715) | 61.792 (22.2612) |
| 20 | 20 | 36.0726 (12.81) | 34.072 (15.784) | 39.4545 (12.1572) | 37.8943 (13.6789) |

Difference between 2017 and 2020 unweighted rates is not statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 79, p = 0.348810195922852). Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 206, p < .05).

###### Table B.27 Summary Statistics by Year: Potentially Preventable Complications (PPC)

###### Summary Statistics by Year: 1.4.3 Potentially Preventable Complications (PPC)

| Year | Sample Size | Unweighted Mean (SD) | Unweighted Median (IQR) | Weighted Mean (SD) | Weighted Median (IQR) |
| --- | --- | --- | --- | --- | --- |
| 17 | 20 | 18.2075 (3.7083) | 19.047 (4.6282) | 17.5511 (3.7026) | 18.2586 (5.0784) |
| 18 | 20 | 12.6584 (2.4733) | 12.8397 (3.4559) | 9.8914 (2.1687) | 9.6868 (3.064) |
| 19 | 20 | 13.1439 (3.4557) | 13.5737 (3.8911) | 10.096 (2.5824) | 10.2814 (2.7027) |
| 20 | 20 | 13.074 (3.1883) | 13.936 (3.8658) | 10.4841 (2.6859) | 10.9682 (3.3402) |

Difference between 2017 and 2020 unweighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 198, p < .05). Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 207, p < .05).

###### Table B.28 Summary Statistics by Year: Potentially Preventable Emergency Department Visits (PPV)

###### Summary Statistics by Year: 1.4.4 Potentially Preventable Emergency Deparment visits (PPV)

| Year | Sample Size | Unweighted Mean (SD) | Unweighted Median (IQR) | Weighted Mean (SD) | Weighted Median (IQR) |
| --- | --- | --- | --- | --- | --- |
| 17 | 20 | 33.4815 (6.4429) | 34.5607 (6.5247) | 18.0933 (3.8163) | 19.0752 (3.4129) |
| 18 | 20 | 31.5729 (5.3191) | 31.3547 (7.0686) | 16.8843 (3.2719) | 16.8523 (3.6006) |
| 19 | 20 | 32.1941 (6.082) | 32.7342 (6.43) | 17.3143 (3.5192) | 17.5248 (4.2915) |
| 20 | 20 | 20.3284 (4.2568) | 20.3203 (3.5104) | 9.9476 (2.236) | 9.7303 (1.3868) |

Difference between 2017 and 2020 unweighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 210, p < .05). Difference between 2017 and 2020 weighted rates is statistically significant after conducting a Paired Wilcoxon Signed Rank Test (V = 210, p < .05).